Expert legal advice from The Competition Lawyers

Category: Price Hikes

Vital Hydrocortisone tablets at the centre of suspected excessive and unfair pricing to the NHS

First published by Admin on March 09, 2018 in the following categories: Price Hikes and tagged with |

overpriced hydrocortisone tablets

The Competition and Markets Authority (CMA) are investigating price-hikes of vital hydrocortisone tablets on the basis that they suspect they are being excessively inflated.

Intas Pharmaceuticals Limited and Accord Healthcare Limited, which acquired Actavis UK in January 2017, are at the centre of the CMA’s investigations. The suspicion is breaches of competition laws through unfair prices over the supply of hydrocortisone tablets in the UK to the NHS.
read more

CMA releases statement of objections for alleged excessive and unfair pricing for hydrocortisone tablets

First published by Admin on October 06, 2017 in the following categories: Price Hikes and tagged with

The Competition and Markets Authority (CMA) issued a statement of objections on 9th August 2017 against Intas Pharmaceuticals Limited and its subsidiary Accord Healthcare Limited (which acquired Actavis UK) for suspected breaches of U.K and E.U competition laws.

The CMA believes that the two companies are charging excessive and unfair prices for hydrocortisone tablets, therefore breaking competition law and affecting consumers and the relevant market.

Any form of excessive pricing is bad, but when it comes to medication, you can argue it’s worse. Medication is there to help people and save lives!
read more

CMA fines Pfizer and Flynn Pharma £90 million for abuse of dominant market position and price hiking

First published by Admin on September 01, 2017 in the following categories: Latest Price Hikes and tagged with

The Competition and Markets Authority (CMA) has cracked down on excessive and unfair pricing allegations over Phenytoin Sodium capsules. Pharmaceutical giants Pfizer and Flynn Pharma are accused of abusing dominant positions in the sector to inflate profits; breaking U.K. and EU competition laws in the process.

The CMA’s investigations were reportedly hampered as Pfizer failed to provide information as requested by the authorities.
read more

CMA are investigating alleged anti-competitive and abusive conduct in relation to the hydrocortisone tablets

First published by Admin on May 11, 2017 in the following categories: Price Hikes and tagged with

The price of a “lifesaving” NHS drug has dramatically increased due to two companies allegedly agreeing not to compete with one another.

The competition watchdog, Competition and Markets Authority (CMA), has set up an investigation into an alleged anti-competitive agreement and abusive conduct in respect of hydrocortisone tablets. There’s a suspected breach of Chapters I and II of the Competition Act (CA), and Articles 101 and 102 of the Treaty of the Functioning of the European Union (TFEU) – competition laws.

Essentially, the companies involved are being accused of forming agreements that prevent competition as well as abusing a dominant position in the market.
read more

The pharmaceutical industry’s £90 million fine for anti-competitive pricing

First published by Admin on December 26, 2016 in the following categories: Price Hikes and tagged with

Pharmaceutical abuse

Earlier this month, the Competition and Markets Authority (CMA) issued an infringement decision that two companies had breached competition laws.

The CMA found that Pfizer (Ltd and Inc) and Flynn Pharma (Ltd and Holdings) both abused their respective dominant positions by imposing unfair prices for phenytoin sodium capsules that they sold in the U.K. This infringed the Chapter II Prohibition of the Competition Act (CA) and Article 102 of the Treaty on the Functioning of the European Union (TFEU).
read more